Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

By Giulio Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A. McCullough, S. Natale, G. Forlani, N. Melchionda. Diabetes, 2001

2,611 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/0ec90953378aabe5aa53c08de712dfe82df35ae8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Oncology

Haiming Cao

Citations in the corpus

Design and validation of a histological scoring system for nonalcoholic fatty liver disease (2005, background): “19 Among the goals of the network were: (1) to form a database for long-term natural history observations of patients with NAFLD; (2) to collect clinical samples for metabolic, immunological, molecular, and genetic studies of NAFLD focusing on defining the etiology of this disease; and (3) to evalua”
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity (2009, background): “Recently, it has become clear that VAT correlates directly with intrahepatic triglyceride (IHTG) content (8-10), and an increase in IHTG is associated with the same metabolic abnormalities linked to an increase in VAT (9-12).”
Disordered lipid metabolism and the pathogenesis of insulin resistance. (2007, neutral): “Nonalcoholic steatohepatitis is also increasingly recognized as a component of the insulin resistance or metabolic syndrome (64, 76, 101).”
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (2006, methodology): “Metabolic syndrome was defined as having at least 3 of the following17: (1) waist circumference 102 cm in men or 88 cm in women; (2) fasting triglycerides 150 mg/dL; (3) fasting HDL 40 mg/dL in men or 50 mg/dL in women; (4) blood pressure 130/85 mm Hg or a diagnosis of hypertension; (5) fasting gluc”
Systematic reviews and meta-analyses (2009, methodology): “The search strategy is detailed in Supplementary Tables 2 to 5.”
Diabetic dyslipidaemia: from basic research to clinical practice* (2003, background): “There has been accumulating evidence showing that hepatic steatosis is a feature of dyslipidaemia and insulin resistance [69, 70, 71].”
A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Owing to its increasing prevalence and strong association with the metabolic syndrome [3], it is now recognized that NAFLD/”
Triglyceride metabolism in the liver (2017, neutral): “The overflow of FA derived from excessive lipolysis in the adipose tissue contributes to the pathogenesis of insulin resistance in mice and humans (159), leading to both type 2 diabetes (213) and NAFLD (27, 171).”